
Today, we shared that the first participant has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101 for #obesity, as well as key new additions to our executive team. Read more here: businesswire.com/news/home/2026…
Rahul Dhanda
1.4K posts

@rahulkdhanda
Co-founder, President, CEO at @syntisbio, Co- founder/Founding CEO @Sherlock_Bio, Co-founder BLASTID, tweets my own. @dhanda.bsky.social

Today, we shared that the first participant has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101 for #obesity, as well as key new additions to our executive team. Read more here: businesswire.com/news/home/2026…




Today we announce a $38 million financing, including a $33M Series A led by Cerberus Ventures. This is an exciting moment for Syntis, accelerating our vision to revolutionize both chronic and #raredisease treatment through safe, effective oral therapies. businesswire.com/news/home/2025…




Today we announced positive preclinical and first-in-human data for our lead candidate, SYNT-101, an investigational once-daily oral treatment for #obesity at the European Congress on Obesity and Weight Management. Read more: businesswire.com/news/home/2025…

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs. wired.com/story/syntis-b…

Vocational schools connect students with blue-collar jobs, while helping to overcome labor shortages. Unless Boston wants to run out of plumbers, it should invest in Madison Park, writes @marcela_elisa. trib.al/UoU8lOB

In today's paper: $700 million for a high school? Boston now seeking state funds to rebuild Madison Park as estimated costs balloon. Mass. lawmakers reach deal on $425 million more for shelter system but also move to rein in costs; and more. trib.al/O7uWsxh





